Senior Scientist (PhD)

Drive the research in our lysin program!


Mehr Jobs von PhagoMed Biopharma GmbH
Siehe Firmendetails

Kontakt: Lorenzo Corsini

PhagoMed is looking for a HIGH-CALIBRE MOLECULAR BIOLOGY SCIENTIST (PhD) TO JOIN OUR TEAM as Senior Scientist (f/m/d) in Vienna, Austria

Do you want to be part of developing a high-profile antibiotics alternative and help drive the research into new synthetic lysins – together with an experienced and motivated team and a network of leading physicians?

Then apply for the position of

SENIOR SCIENTIST (f/m/d)

WHAT WE ARE LOOKING FOR

Mandatory requirements

  • PhD or equivalent in microbiology, cell biology, protein biochemistry or structural biology;
  • Excellent publication track record in a relevant field;
  • Highly structured thinking;
  • Interest in targeted pharmaceutical development;
  • Interest in working in a team of highly skilled and motivated professionals;
  • Fluent in English

Welcome add-on qualifications

  • Experience with endolysins or other types of recombinant proteins
  • Experience in molecular cloning, combinatorial methods, library screening
  • Experience in research on antibiotics, e.g. resistance formation
  • Experience in bacterial genetics, bioinformatics or genomic analysis
  • Experience in pharmaceutical research in a start-up/ company

ROLE DESCRIPTION

  • Establish research processes according to the latest microbiological technology developments (e.g. robotics and genomic data);
  • Set-up and run library screenings for specific pathogens using the proprietary LysinBuilder toolkit
  • Further establish and validate potency model for endolysins against bacteria in (mucosal) biofilm and planktonic growth;
  • Assembly of bacterial panels for species of interest, including in silico analysis of geno- and serotypes, to ensure required genetical and geographical breadth;
  • Genomic analyses of target bacteria and microbiome samples
  • Analyze effect of endolysins on bacteria, including MIC, MBC, Cmax, AUC, resistance formation, in planktonic growth and on mucosal biofilms
  • Evaluate immune response to endolysins
  • Establish standardized experimental protocols that will enable reproducibility in later GLP studies (e.g. potency, endolysin effect on the immune system);
  • Documentation of results according to the PhagoMed Quality Standards (GLP-like), to ensure the quality of results and their documentation are acceptable to regulatory authorities, working towards a human clinical trial application;
  • Supervise research assistants, including training on working with bacteria, endolysins and phages, working in a BSL-2 environment, application of experimental and documentation standards;
  • Drafting of patent claims as appropriate, publication of selected results in scientific journals;

WHAT WE OFFER

  • Become part of developing a new asset class in anti-infectives
  • Take full responsibility for key elements of the PhagoMed development plan
  • Pioneer new methods and processes to industrialize key research techniques
  • Be part of a highly motivated, multinational and fun team that believes phage-based therapies can be part of the solution to the global antibiotics crisis
  • A competitive compensation package that reflects the qualifications and seniority of the candidate. Due to legal requirements, we are required to state that the minimum salary for this job is a monthly salary of EUR 3.500,-- gross.

 

WHAT MOTIVATES US TO DEVELOP LYSIN-BASED PHARMACEUTICALS?

Antibiotics fail in many dimensions: many bacteria are resistant, they mostly don’t work on biofilms, and they disrupt the microbiome by non-selectively killing all bacteria. In contrast, phage endolysins lyse bacteria with a high selectiveness, while not harming the beneficial microbiome, even in biofilms, even when the bacteria are antibiotic resistant. We develop synthetic, improved variants of natural endolysins, to treat chronic or persistent bacterial infections. Our lead asset is PM-477, which we develop for the treatment of bacterial vaginosis (see article) There are many other diseases where patients could benefit from this emerging class of precision antimicrobials.

WHO AND WHAT IS PHAGOMED?

Who is PhagoMed

PhagoMed Biopharma GmbH is an Austrian biotech company focused on synthetic lysins against chronic indications with high medical need. The company has developed a proprietary platform to develop synthetic lysins for any bacterial pathogen by using a combination of in-silico prediction, synthetic assembly and directed evolution. Its development pipeline focuses on chronic bacterial infections where suppressive antibiotics fail to cure and frequently destroy the natural microbiomes. Its lead program, PM-477, is a novel breakthrough therapy for recurrent bacterial vaginosis.

PhagoMed’s Vision

TO DEVELOP BREAKTHROUGH THERAPIES FOR CHRONIC BACTERIAL INFECTIONS.

 

INTERESTED? Please contact us!

To submit your application, please click on the following link:

Online-Application

Please also feel free to reach out directly if you have specific questions:

Dr. Lorenzo Corsini,

CEO | Research & Development, PhagoMed Biopharma GmbH

corsini@phagomed.com


BEWERBEN
Bitte beziehen Sie sich bei Ihrer Bewerbung auf jobcity.at

ARBEITGEBER


MÖGLICHKEITEN ARBEITGEBER

PARTNER

KONTAKT

REGISTRIERUNG

JOBPLATTFORM


VISION

BILDUNG

FACEBOOK

BETREIBER


© EPIFRAME.COM

IMPRESSUM

WEITERE PLATTFORMEN


JOBCITY.AT

BIOTECHJOBS.AT

IT-KARRIERE.AT

BUSINESSJOBS.AT

TUCO DRINKS